Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42:abril. [Ref.ID 103082]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103035]

Anónimo. FDA mandates new warnings for fluoroquinolones concerning mental health and low blood sugar. DIA Daily 2018:1. [Ref.ID 102712]

Anónimo. Fluoroquinolone antibacterial drugs for systemic use: Drug safety communication - Warnings updated due to disabling side effects. FDA MedWatch alert 2016:26 de julio. [Ref.ID 100508]

Nadal M, Cols M. Hacia una mejor atención a los pacientes: medicamentos que hay que evitar y posibles alternativas.. Formación Médica Continuada en Atención Primaria 2016;23:231-44. [Ref.ID 100328]

Anónimo. Fluoroquinolone antibacterial drugs: Drug safety communication - FDA advises restricting use for certain uncomplicated infections. U.S. Food and Drug Administration 2016:1. [Ref.ID 100269]

Inghammar M, Svanström H, Melbye M, Pasternak B, Hviid A. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ 2016;352:i843. [Ref.ID 100141]

Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]

Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y, Van Rensburg J, Rowe BH, Flores-Figueroa J, Rewerska B, Clark K, Keedy K, Sheets A, Scott D, Horwith G, Das AF, Jamieson B, Fernandes P, Oldach D, for the SOLITAIRE-ORAL Pneumonia Team. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). The Lancet Infectious Diseases 2016;16:421-30. [Ref.ID 99992]

Dawson R, Diacon AH, Everitt D, van Niekerk C, Ronald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp LI, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015;385:1738-47. [Ref.ID 99082]

Anónimo. Infection d'une plaie du pied chez un patient diabétique. Prescrire 2014;34:674-80. [Ref.ID 98093]

Anónimo. Cystites simples récidivantes chez les femmes. Prescrire 2013;33:835-7. [Ref.ID 96497]

Anónimo. FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. U.S. Food and Drug Administration 2013:15 de agosto. [Ref.ID 96190]

Kuehn BM. FDA warning and study highlight fluoroquinolone risks. JAMA 2013;310:1014. [Ref.ID 96081]

Chou H-W, Wang J-L, Chang C-H, Lee J-J, Sau W-Y, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis 2013;57:971-80. [Ref.ID 95903]

Celaya Lecea MC, Martínez Basterra J. Medicamentos y prolongación del intervalo QT. Boletín de Información Farmacoterapéutica de Navarra 2013;21:1-7. [Ref.ID 95707]

Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]

Loghin C, Haber H, Beasley Jr CM, Kothare PA, Kauffman L, April J, Jin L, Allen AJ, Mitchell MI. Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. Br J Clin Pharmacol 2013;75:549-64. [Ref.ID 94857]

Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründing M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T, for the German Study Group Competence Network Sepsis (SepNet). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 2012;307:2390-9. [Ref.ID 93235]